As explained by Elena Efimovna Petryaykina, director of the Russian Children’s Clinical Hospital (RCCH), a branch of the Russian National Research Medical University. NI Pirogova, type 1 diabetes is based on an autoimmune reaction in which the immune system destroys pancreatic cells that produce insulin. This leads to insulin deficiency and impaired glucose absorption.
Rituximab works by removing lymphocytes from the body that are involved in an autoimmune attack. Preclinical studies have shown that the drug can increase beta cell survival and slow disease progression.
Clinical research is carried out on the basis of the Russian Children’s Clinical Hospital. It includes adolescents between the ages of 12 and 17 who are diagnosed with type 1 diabetes. Patients are divided into two groups; One is receiving insulin therapy alone, and the other is receiving insulin therapy with the addition of rituximab. The research will continue for three years, and if the results confirm its effectiveness, the method will enter clinical practice to prevent complications and maintain insulin production in diabetic patients.
Source: Ferra
I am a professional journalist and content creator with extensive experience writing for news websites. I currently work as an author at Gadget Onus, where I specialize in covering hot news topics. My written pieces have been published on some of the biggest media outlets around the world, including The Guardian and BBC News.
